This pre-doctoral Pharmacological Sciences Training Program (PSTP) is a cross-disciplinary program that represents a merger of research training opportunities in the Schools of Medicine (Pharmacology) and Pharmacy (Medicinal Chemistry and Pharmaceutics) at the University of Washington. The rationale for this program is that it is essential for providing in-depth training in several inter-related disciplines that are central to current and future research related to the discovery, validation and development of new drug targets and new chemical entities that will improve global health. This focus distinguishes training provided by the PSTP from other pre-doctoral training grants available at UW. The primary objective of the PSTP is to develop scientists, equipped with the necessary background in the biological and chemical sciences and training in the application of modern tools of research and instrumental techniques, to undertake and direct fundamental research related to drug action, metabolism and pharmacokinetics. Trainees follow tracks that emphasize training in four broadly defined areas: (I) cellular and molecular pharmacology, (II) structure and drug/vaccine design, (III) drug metabolism, (IV) pharmacokinetics, drug transport and delivery, which exist in the departments of Pharmacology, Medicinal Chemistry and Pharmaceutics. Didactic components involve individualized, highly multidisciplinary programs of coursework and seminars that are centered on the biological and chemical sciences. The program brings together some 40 well-funded faculty members whose research emphasizes training in mechanisms and regulation of cell signaling, neuropharmacology, structural analysis of pharmacologically relevant protein-ligand interactions, mechanistic and bio- analytical aspects of drug metabolism and toxicology, pharmacogenetics, pharmacokinetics/dynamics and drug transporter function and regulation. Under-represented and disadvantaged students, who are actively recruited through a number of faculty activities, currently represent ~10% of the training grant eligible pool of some 70 students. In this revised, competitive renewal of the Pharmacological Sciences National Research Service Award program, support is requested for 16 pre-doctoral trainees per year. The selection of trainees will be on a competitive basis from the pool of students in years 1-3, who are committed to research in one of the aforementioned areas.
The training that is provided relates to how drugs used to treat human diseases and other disorders act on the body (pharmacology), and how the body acts on drugs (metabolism and pharmacokinetics). These fundamental areas of knowledge are critical to optimizing the use of drugs already on the market as well as ongoing national and international efforts to discover and develop new therapeutic agents.
|Goulet, Dennis R; Orcutt, Steven J; Zwolak, Adam et al. (2018) Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies. J Biol Chem 293:651-661|
|Rubinstein, M; Patowary, A; Stanaway, I B et al. (2018) Association of rare missense variants in the second intracellular loop of NaV1.7 sodium channels with familial autism. Mol Psychiatry 23:231-239|
|Lee, Nora; Hebert, Mary F; Wagner, David J et al. (2018) Organic Cation Transporter 3 Facilitates Fetal Exposure to Metformin during Pregnancy. Mol Pharmacol 94:1125-1131|
|Aliwarga, Theresa; Evangelista, Eric A; Sotoodehnia, Nona et al. (2018) Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes. Int J Mol Sci 19:|
|Wagner, David J; Shireman, Laura M; Ahn, Sojung et al. (2018) Disposition of Methamphetamine and Major Metabolites in Mice: Role of Organic Cation Transporter 3 in Tissue-Selective Accumulation of Para-Hydroxymethamphetamine. Drug Metab Dispos 46:1277-1284|
|Gao, Yu; Kraft, John C; Yu, Danni et al. (2018) Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy. Eur J Pharm Biopharm :|
|Wong, Timothy; Wang, Zhican; Chapron, Brian D et al. (2018) Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metab Dispos 46:367-379|
|Abraham, Antony D; Fontaine, Harrison M; Song, Allisa J et al. (2018) ?-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition. Neuropsychopharmacology 43:362-372|
|Evangelista, Eric A; Lemaitre, Rozenn N; Sotoodehnia, Nona et al. (2018) CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity. Drug Metab Dispos 46:380-386|
|Henderson, Lindsay M; Claw, Katrina G; Woodahl, Erica L et al. (2018) P450 Pharmacogenetics in Indigenous North American Populations. J Pers Med 8:|
Showing the most recent 10 out of 149 publications